Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price & Analysis

Alnylam Pharmaceuticals, Inc. (ALNY) rose 0.00% to USD 271.77 as of July 25, 2026 at 02:24 UTC, according to Nexqual real-time market data.

ALNY last closed at USD 271.77; the session ranged USD 265.64–275.53 on volume of 1,094,509 shares. Market capitalization is —, with a 52-week range of USD 262.21–495.55 (NMS). Source: Nexqual, July 25, 2026 at 02:24 UTC.

Key Statistics (as of July 25, 2026 at 02:24 UTC)

Technical Analysis (ALNY)

Nexqual's technical model rates ALNY "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 02:24 UTC.

From Alnylam Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)

Key Strengths & Strategy (as disclosed to the SEC)

• In March 2025, the United States Food and Drug Administration, or the FDA, approved our supplemental New Drug Application, or sNDA, for AMVUTTRA for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
• In parallel, we advanced a proprietary technology that conjugates a sugar molecule, referred to as GalNAc, to the siRNA molecule.
• We believe this success will enable us to sustainably and organically create and commercialize transformative medicines that benefit patients around the world across a broad range of disease areas and indications.

Partnerships

• In addition, we are exploring peptide and antibody-based approaches for targeted siRNA delivery to new tissues, including as part of our collaboration with PeptiDream, Inc., which aims to discover and develop novel conjugates for targeted delivery of RNAi therapeutics to a broader range of tissues.
• We also intend to continue to build on our progress with extrahepatic delivery during 2026, advancing our CNS programs under our collaboration with Regeneron, as well as continuing to advance our other extrahepatic delivery initiatives, in support of our Alnylam 2030 goal to expand to ten tissue types by the end of 2030.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:24 UTC. This page is informational and not investment advice.